Agreements cover clinical production with SynCo Bio Partners and Diosynth.
Cleveland BioLabs (CBLI) and SynCo Bio Partners completed the transfer of technology in their joint effort to produce CBLI’s lead product, Protectan CBLB502, and have signed an agreement to produce sufficient amounts for clinical trials and the commercial market.

SynCo will work with CBLI to develop the manufacturing process, as well as manufacture CBLB502 for Phase I trials and commercial release.

Viron Therapeutics signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing of VT-111. Under the agreement, Diosynth Biotechnology will support the process improvement, process development, and clinical product manufacturing.

Previous articleDebiopharm Signs Four International Marketing Agreements for EVB Drug
Next articleEvoGenix Finetunes a GSK Therapeutic